The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Bassaganya-riera Josep since 2021.
This trader's CIK number is 1843575.
At the time of last reporting, Bassaganya-riera Josep was the 10% Owner of Landos Biopharma, Inc.. (stock ticker symbol LABP).
Also see all insider trading activities at Landos Biopharma, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | LABP | 0 | $0 | 5,720,868 | $0 | 0 | $0 |
| 2021 | LABP | 0 | $0 | 521,715 | $3,074,321 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-02-28 | LABP | Sale | 5,720,868 | .00 | 0 |
| 2021-12-16 | LABP | Sale | 24,301 | 5.11 | 124,251 |
| 2021-12-17 | LABP | Sale | 36,000 | 4.84 | 174,096 |
| 2021-12-20 | LABP | Sale | 33,194 | 4.75 | 157,804 |
| 2021-12-13 | LABP | Sale | 40,000 | 5.37 | 214,840 |
| 2021-12-14 | LABP | Sale | 42,000 | 5.10 | 214,284 |
| 2021-12-15 | LABP | Sale | 43,000 | 5.02 | 216,032 |
| 2021-12-09 | LABP | Sale | 11,162 | 6.26 | 69,829 |
| 2021-12-10 | LABP | Sale | 40,000 | 5.77 | 230,799 |
| 2021-12-06 | LABP | Sale | 36,000 | 6.17 | 221,976 |
| 2021-12-07 | LABP | Sale | 42,000 | 6.58 | 276,528 |
| 2021-12-08 | LABP | Sale | 25,530 | 6.65 | 169,723 |
| 2021-12-01 | LABP | Sale | 32,237 | 7.01 | 226,110 |
| 2021-12-02 | LABP | Sale | 29,861 | 6.45 | 192,633 |
| 2021-12-03 | LABP | Sale | 36,000 | 6.15 | 221,364 |
| 2021-11-29 | LABP | Sale | 15,430 | 7.58 | 116,882 |
| 2021-11-30 | LABP | Sale | 35,000 | 7.06 | 247,170 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Bassaganya-riera Josep (10% Owner of Landos Biopharma, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.